The role of protein glycosylation in colorectal cancer: From molecular pathways to clinical applications

IF 9.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-09-08 DOI:10.1016/j.bbcan.2025.189438

Tiangui Wu , Jianguo Gu , Yuhan Sun , Pengfei Ye

{"title":"The role of protein glycosylation in colorectal cancer: From molecular pathways to clinical applications","authors":"Tiangui Wu , Jianguo Gu , Yuhan Sun , Pengfei Ye","doi":"10.1016/j.bbcan.2025.189438","DOIUrl":null,"url":null,"abstract":"<div><div>Glycosylation, a pivotal post-translational modification, critically influences colorectal cancer (CRC) progression via dysregulated <em>N</em>- and <em>O</em>-linked pathways, characterized by oligomannose, fucosylation, hypersialylation, truncated <em>O</em>-glycans (Tn, sialyl-Tn), branched <em>N</em>-glycans, and Lewis antigens. These alterations promote tumor aggressiveness, immune evasion, and metastasis through glycoprotein remodeling (e.g., mucins, integrins) and dysregulating glycosyltransferases (such as Fut2, ST6GAL1). Clinically, tumor-associated glycans offer diagnostic potential, with glycomic profiling enhancing early detection. Glycosylation further orchestrates the CRC microenvironment by modulating interactions among tumor cells, microbiota, and immune components. This review focuses exclusively on protein-centric glycosylation and highlights current studies on the roles of glycosylation in CRC, encompassing molecular mechanisms, diagnostic biomarkers, and emerging therapeutic strategies targeting glycosylation enzymes or glycan epitopes. Understanding glycan dysregulation provides new perspectives for biomarker development and targeted interventions in precision oncology.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189438"},"PeriodicalIF":9.7000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Reviews on cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304419X25001805","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Glycosylation, a pivotal post-translational modification, critically influences colorectal cancer (CRC) progression via dysregulated N- and O-linked pathways, characterized by oligomannose, fucosylation, hypersialylation, truncated O-glycans (Tn, sialyl-Tn), branched N-glycans, and Lewis antigens. These alterations promote tumor aggressiveness, immune evasion, and metastasis through glycoprotein remodeling (e.g., mucins, integrins) and dysregulating glycosyltransferases (such as Fut2, ST6GAL1). Clinically, tumor-associated glycans offer diagnostic potential, with glycomic profiling enhancing early detection. Glycosylation further orchestrates the CRC microenvironment by modulating interactions among tumor cells, microbiota, and immune components. This review focuses exclusively on protein-centric glycosylation and highlights current studies on the roles of glycosylation in CRC, encompassing molecular mechanisms, diagnostic biomarkers, and emerging therapeutic strategies targeting glycosylation enzymes or glycan epitopes. Understanding glycan dysregulation provides new perspectives for biomarker development and targeted interventions in precision oncology.

查看原文本刊更多论文

蛋白糖基化在结直肠癌中的作用：从分子途径到临床应用。

糖基化是一种关键的翻译后修饰，通过失调的N-和o -连接途径严重影响结直肠癌（CRC）的进展，其特征是寡甘露糖、聚焦化、高唾液酰化、截断的o -聚糖（Tn、唾液酰-Tn）、支链N-聚糖和Lewis抗原。这些改变通过糖蛋白重塑（如粘蛋白、整合素）和糖基转移酶失调（如Fut2、ST6GAL1）促进肿瘤侵袭性、免疫逃避和转移。在临床上，肿瘤相关的聚糖具有诊断潜力，糖谱分析增强了早期发现。糖基化通过调节肿瘤细胞、微生物群和免疫成分之间的相互作用，进一步协调结直肠癌微环境。这篇综述专注于以蛋白质为中心的糖基化，并重点介绍了糖基化在结直肠癌中的作用，包括分子机制，诊断生物标志物，以及针对糖基化酶或聚糖表位的新兴治疗策略。了解聚糖失调为精准肿瘤学的生物标志物开发和靶向干预提供了新的视角。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochimica et biophysica acta. Reviews on cancer 医学-生化与分子生物学

CiteScore

17.20

自引率

0.00%

发文量

138

审稿时长

33 days

期刊介绍： Biochimica et Biophysica Acta (BBA) - Reviews on Cancer encompasses the entirety of cancer biology and biochemistry, emphasizing oncogenes and tumor suppressor genes, growth-related cell cycle control signaling, carcinogenesis mechanisms, cell transformation, immunologic control mechanisms, genetics of human (mammalian) cancer, control of cell proliferation, genetic and molecular control of organismic development, rational anti-tumor drug design. It publishes mini-reviews and full reviews.